Niagen Bioscience, Inc. (NAGE) Stock Price & Analysis
Niagen Bioscience, Inc. (NAGE) closed at USD 2.58 on Thursday, October 15, 2026, up 1.98% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.53; the Oct 15, 2026 session ranged USD 2.53–2.6 on volume of 444,189 shares. Market capitalization is $204.15M, with a 52-week range of USD 2.51–7.95 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NAGE.md
Key facts (NAGE)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (6 analysts), mean target USD 12.08 (range 8.5–22).
- Total return with dividends: 1Y -65.2% vs S&P 500 +18.1%; 5Y -59.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.03, revenue estimate $34.3M.
Analysts (NAGE)
Consensus Buy (mean 2.00 on a 1–5 scale), 6 analysts; mean target USD 12.08 (low 8.5, high 22).
Total return (dividends reinvested) (NAGE)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -65.2% | -59.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -65.4% | -16.5% |
| Volatility (annualized) | 47.8% | 66.3% |
| Max drawdown | -66.7% (Oct 2025→Oct 2026) | -81.9% (Jun 2025→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 2.58 |
|---|---|
| Change | ▲ 1.98% (up) |
| Previous Close | USD 2.53 |
| Open | USD 2.54 |
| Day Range | USD 2.53 – 2.6 |
| 52-Week Range | USD 2.51 – 7.95 |
| Volume | 444,189 shares |
| Market Cap | $204.15M |
| Exchange | NCM |
Technical Analysis (NAGE)
Nexqual's technical model rates NAGE "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.56 (oversold) |
| vs SMA50 | Below (USD 2.99) |
| MACD | -0.13 (negative) |
Analyst Ratings (NAGE)
Wall Street analysts rate NAGE "Buy" based on 6 analysts, with a mean price target of USD 12.08 (range USD 8.5–22), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 12.08 |
| High Target | USD 22 |
| Low Target | USD 8.5 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (NAGE)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -0.03 |
| Revenue Estimate | $34.27M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.01 vs est -0.01 ▲ beat |
| 2026-03-31 | USD 0.02 vs est 0.06 ▼ miss |
| 2025-12-31 | USD 0.03 vs est 0.02 ▲ beat |
| 2025-09-30 | USD 0.05 vs est 0.02 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (NAGE)
| Total Revenue | $129.08M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -4.30% |
| Gross Margin | +64.24% |
| Operating Margin | +2.35% |
| Profit Margin | +12.39% |
| ROE | +21.80% |
| Debt / Equity | 0.03 |
| Current Ratio | 6.5 |
| Total Cash | $66.59M |
| Total Debt | $2.33M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (NAGE)
Nexqual rates Niagen Bioscience, Inc.'s overall financial health "Strong" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Strong — Revenue +30% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 64%, operating 2% |
| Balance Sheet | Strong — $67M cash vs $2M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $6M (TTM) |
| Efficiency | Strong — ROE 22%, ROA 5.4% |
Ownership (NAGE)
| Insider Ownership | +29.45% |
|---|---|
| Institutional Ownership | +41.49% |
| Shares Outstanding | 79.13M |
| Float | 59.07M |
| Short % of Float | +7.54% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (NAGE)
Niagen Bioscience, Inc. is led by Robert N. Fried (age 65), CEO & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO & Director | Robert N. Fried (age 65) |
|---|---|
| Co-Founder & Chairman | Frank Louis Jaksch (age 57) |
| CFO & Principal Accounting Officer | Ozan Pamir C.F.A. (age 33) |
| Senior Vice President of Global Regulatory & Scientific Affairs | Andrew Shao |
| Chief Marketing Officer | Michiko Kelley |
Major Backers & Investors (NAGE)
Notable institutional backers of Niagen Bioscience, Inc. include SteelPeak Wealth, LLC, Tieton Capital Management, LLC, Qube Research & Technologies Ltd, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SteelPeak Wealth, LLC | 4.39% |
| Tieton Capital Management, LLC | 2.52% |
| Qube Research & Technologies Ltd | 2.04% |
| UBS Group AG | 1.61% |
| Goldman Sachs | 1.59% |
| Arrowstreet Capital, Limited Partnership | 1.47% |
| Fidelity | 1.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.96% |
| BlackRock | 7.78% |
| Geode Capital | 1.86% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CPB | The Campbell's Company | USD 19.84 | ▲ 4.7% |
| INGR | Ingredion Incorporated | USD 97.27 | ▲ 0.01% |
| CAG | ConAgra Brands, Inc. | USD 14.18 | ▲ 3.5% |
| PPC | Pilgrim's Pride Corporation | USD 28.89 | ▲ 0.35% |
| SFD | Smithfield Foods, Inc. | USD 18.48 | ▲ 1.43% |
| LW | Lamb Weston Holdings, Inc. | USD 54.21 | ▲ 4.33% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt